There is a major limitation: the analysis included past and recent users of 5ARIs, as well as current users. Past users are defined as those who stopped taking a 5ARI at least 91 days before getting diagnosed or treated for ED. Recent users are those who last took the drug 31-90 days before diagnosis or treatment for ED.
Prescrire, an independent patient safety organization based in France, has updated its Drugs to Avoid guide. Finasteride appears in the 2024 edition, and has also been included in past editions. The guide notes: Finasteride 1 mg, a 5-alpha reductase inhibitor, has very modest efficacy in androgenic alopecia in men: it increases hair density on the … Read more
Some post-5ARI patients experience genital numbness. This symptom can be assessed, but the tests are not easily accessible. This post gives an overview of medical tests which could yield signs of genital numbness and other abnormalities.
SUMMARY: Post-drug disorders are not side effects that linger, but lasting changes that may be severe and irreversible. These disorders are linked to prescribed drugs as well as recreational drugs, and can arise after one dose, long-term use, or abuse. This post covers post-drug disorders linked to use of alcohol, hallucinogens, antidepressants, benzodiazepenes, isotretinoin (also … Read more
The websites Drugs.com and Ask a Patient collect reviews of drugs. Here are selected reviews of finasteride, taken by men for hair loss conditions. The dates range from 2008 to 2023.
Along with finasteride and saw palmetto, dutasteride has been linked a post-drug disorder in some men. This post contains firsthand reports of lasting dysfunctions after taking dutasteride, and stopping the drug.
Men turn to saw palmetto, a plant-based supplement, because prescription drugs may be unavailable or too costly. Some see the palm supplement as having a lower risk of side effects. Regulators say it is safe, but online, it is not difficult to find reports of men with adverse experiences after using saw palmetto which resemble the post-finasteride disorder.
Six months after discontinuing a Phase 3 finasteride trial, a man’s sexual adverse experience was unresolved. There were also 16 men whose drug-related sexual adverse experiences were unresolved at the conclusion of the trial.
Filings from lawsuits alleging persistent adverse effects of Propecia and Proscar in various jurisdictions in the United States and Canada, dating from 2011 to 2021.
In 2006, the Swedish Medical Products Agency asked Merck for an analysis of all adverse events affecting the male reproductive system which persisted after stopping Propecia. In subsequent documents, there is a back-and-forth between Merck and the Agency as to the validity of these reports and the overall safety concern. Merck used an arsenal of arguments to discount these reports and claim its own data is superior to postmarketing data.